OSE IMMUNOTHERAPEUTICS Aktie

>OSE IMMUNO Aktienkurs

3.238 EUR -1.0% (TradegateBSX)

Ask: 3.312 EUR / 170 Stück

Bid: 3.282 EUR / 170 Stück

Tagesumsatz: 720 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

OSE IMMUNO Aktie über LYNX handeln

Intraday

1 Jahr

>OSE IMMUNO Performance

1 Woche: +9,8%

1 Monat: -24,2%

3 Monate: -38,6%

6 Monate: -53,5%

1 Jahr: -41,8%

laufendes Jahr: -39,3%

>OSE IMMUNOTHERAPEUTICS Aktie

Name:

OSE IMMUNOTHERAPE.EO -,20

Land:

Frankreich

Sektor:

Gesundheit

ISIN/ Wkn:

FR0012127173 / A14QXP

Symbol/ Ticker:

6OP (Frankfurt)

Kürzel:

FRA:6OP, ETR:6OP, 6OP:GR

Index:

Webseite:

https://ose-immuno.com/

Profil:

OSE Immunotherapeutics SA is a clinical-stage biotechnology company based in Nantes and Paris, France, specializing in the development of first-in-class immunotherapies for immuno-oncology and immuno-inflammation. The company focuses on innovative as..
>Volltext..

Marktkapitalisierung:

73.36 Mio. EUR

Unternehmenswert:

Umsatz:

EBITDA:

Nettogewinn:

Gewinn je Aktie:

Schulden:

Liquide Mittel:

Operativer Cashflow:

Bargeldquote:

Umsatzwachstum:

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

Suchwörter:

OSE IMMUNOTHERAPEUTICS, OSE IMMUNO

Letzte Datenerhebung:

04.04.26

>OSE IMMUNO Kennzahlen

Aktien/ Unternehmen:

Aktien: 22.44 Mio. St.

Frei handelbar: 72.53%

Leerverk. Aktien: -

Rückkaufquote: -

Mitarbeiter: 64

Umsatz/Mitarb.: 0.98 Mio. EUR

Analysten:

Analystenrating: Strong buy

Kursziel: 314.23%

Bewertung:

KGV: -

KGV lG: -

KUV: -

KBV: -

PEG-Ratio: -

EV/EBITDA: -

Rentabilität:

Bruttomarge: -

Gewinnmarge: -

Operative Marge: -

Managementeffizenz:

Gesamtkaprendite: -

Eigenkaprendite: -

>OSE IMMUNO Peer Group

Gesundheit, Antikörper- Behandlung, Autoimmunerkrankungen, Onkologie/ Krebs- Behandlung, Impfstoffentwicklung/ Impfstoffhersteller

>OSE IMMUNO Chart & Kurs - Tradegate

>OSE IMMUNO News

23.03.26 - 18:03	OSE Immunotherapeutics to Present at Upcoming Investor Conferences (GlobeNewswire EN)
	OSE Immunotherapeutics to Present at Upcoming Investor Conferences...

16.03.26 - 07:33	OSE Immunotherapeutics Announces its 2026 Financial Calendar (GlobeNewswire EN)
	OSE Immunotherapeutics Announces its 2026 Financial Calendar...

10.03.26 - 07:33	OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth (GlobeNewswire EN)
	OSE Immunotherapeutics Confirms Marc Le Bozec as Chief Executive Officer to Lead Next Phase of Strategic Growth...

02.03.26 - 18:03	OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi® (GlobeNewswire EN)
	OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late Stage Value Drivers Lusvertikimab and Tedopi®...

26.02.26 - 18:03	OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer (GlobeNewswire EN)
	OSE Immunotherapeutics Receives Second Positive IDMC Recommendation for Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer...

29.01.26 - 07:33	OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab (GlobeNewswire EN)
	OSE Immunotherapeutics Selects Chronic Pouchitis and Hidradenitis Suppurativa as New Key Indications for Lusvertikimab...

21.01.26 - 18:03	OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) (GlobeNewswire EN)
	OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)...

09.12.25 - 07:33	OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation (GlobeNewswire EN)
	OSE Immunotherapeutics Unveils 2026–2028 Strategic Plan With Four Opportunities for Value Creation...

08.12.25 - 14:30	AbbVie-Deal belastet: Aktie von Ose Immunotherapeutics gibt nach (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

08.12.25 - 07:33	OSE Immunotherapeutics Announces Strategic Amendment to AbbVie′s Partnership on ABBV-230 Development (GlobeNewswire EN)
	Strategic Amendment Enhances OSE Immunotherapeutics' Role in ABBV-230 Development While Preserving AbbVie's Long-Term Commitment...

17.11.25 - 18:03	OSE Immunotherapeutics Announces Positive Recommendation from Independent Data Monitoring Committee (IDMC) to Continue Pivotal Phase 3 ARTEMIA Trial Evaluating Tedopi® in Non-Small Cell Lung Cancer (GlobeNewswire EN)
	OSE Immunotherapeutics annonce que le Comité indépendant d'experts scientifiques (IDMC) recommande la poursuite d'ARTEMIA, l'essai pivot de Phase 3 de Tedo...

07.11.25 - 18:03	OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines (GlobeNewswire EN)
	OSE Immunotherapeutics Presents a Poster on OSE-Cytomask®, a Novel “Cis-Demasking” Cytokine Technology to Increase Therapeutic Index of Immunocytokines...

15.10.25 - 19:03	OSE Immunotherapeutics Reports First Half 2025 Financial Results (GlobeNewswire EN)
	OSE Immunotherapeutics Reports First Half 2025 Financial Results...

03.10.25 - 09:42	OSE Immunotherapeutics replaces CEO Nicolas Poirier, appoints Marc Le Bozec as interim CEO (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

26.09.25 - 07:03	OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy (GlobeNewswire EN)
	OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in Immunotherapy...

25.09.25 - 18:03	OSE Immunotherapeutics publie sa position de trésorerie au 30 juin 2025 (GlobeNewswire EN)
	OSE Immunotherapeutics Reports its Cash Position as of June 30, 2025...

23.09.25 - 22:33	OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court (GlobeNewswire EN)
	OSE Immunotherapeutics acknowledges the decision of the Nantes Commercial Court...

22.09.25 - 08:03	Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting (GlobeNewswire EN)
	Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting...

11.09.25 - 18:03	OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer (GlobeNewswire EN)
	OSE Immunotherapeutics and the FoRT Foundation Announce Completion of Enrollment in Combi-TED, a Phase 2 Clinical Trial Evaluating Tedopi® in Combination with Nivolumab or Docetaxel in Patients with Non-Small Cell Cancer...

09.09.25 - 20:33	OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance - Publication of Circular for Combined Annual General Meeting of September 30, 2025 (GlobeNewswire EN)
	OSE Immunotherapeutics Board Urges Support for Value-Driving Strategy and Open-Minded Governance Publication of Circular for Combined Annual General Meeting of September 30, 2025...

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Die Frauen bewundern einen Mann wegen seiner Stärke, aber sie lieben ihn wegen seiner Schwächen. - Beatrice Brown

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram